Table 1.
Thrombocytopenia and suppressed erythropoiesis in LCMV-infected mice
| Treatment | n | Days p.i. | Platelets, 103/μl | RC, 103/μl | OAS BM | IFN-α, ng/ml |
|---|---|---|---|---|---|---|
| NaCl | 6 | 1 | 1,380 ± 68 | nd | nd | und |
| 6 | 2 | 1,289 ± 35 | nd | 1 | und | |
| 6 | 3 | 1,308 ± 41 | 106 ± 5 | nd | nd | |
| 6 | 4 | 1,209 ± 98 | 105 ± 7 | nd | und | |
| 6 | 5 | 1,321 ± 87 | 110 ± 4 | nd | nd | |
| 6 | 6 | 1,298 ± 91 | 108 ± 8 | 1 | nd | |
| α-Irr + LCMV, 106 PFU | 6 | 1 | 1,305 ± 48 | nd | nd | 110 ± 20 |
| 6 | 2 | 1,275 ± 66 | nd | 13.8 ± 0.9 | 470 ± 30 | |
| 6 | 3 | 954 ± 78 | 38 ± 6 | nd | nd | |
| 6 | 4 | 234 ± 52 | 38 ± 7 | nd | 50± 10 | |
| 6 | 5 | 218 ± 37 | 45 ± 4 | nd | nd | |
| 6 | 6 | 224 ± 49 | 46 ± 9 | 8.9 ± 1.1 | nd | |
| α-PLT + LCMV, 106 PFU | 6 | 1 | 7 ± 2 | nd | nd | 100 ± 10 |
| 6 | 2 | 8 ± 3 | nd | 13.5 ± 0.8 | 510 ± 40 | |
| 6 | 3 | 6 ± 1 | 39 ± 7 | nd | nd | |
| 6 | 4 | 6 ± 4 | 40 ± 8 | nd | 70 ± 20 | |
| 6 | 5 | 4 ± 2 | 43 ± 7 | nd | nd | |
| 6 | 6 | 18 ± 9 | 41 ± 5 | 7.8 ± 1.3 | nd | |
| α-PLT + NaCl | 6 | 1 | 9 ± 5 | nd | nd | und |
| 6 | 2 | 7 ± 2 | nd | 1 | und | |
| 6 | 3 | 7 ± 4 | 104 ± 9 | nd | nd | |
| 6 | 4 | 8 ± 1 | 102 ± 7 | nd | und | |
| 6 | 5 | 11 ± 2 | 109 ± 8 | nd | nd | |
| 6 | 6 | 13 ± 5 | 109 ± 7 | 1 | nd |
Platelet and RC counts (mean ± SD) in blood, OAS expression (fold-induction over NaCl-injected mice) assessed by RPA in total BM RNA, and serum circulating levels of IFN-α (mean ± SD) were assessed individually after the indicated treatment. und, undetectable; nd, not done; p.i., postinfection.